Effect of the consumption of a fermented dairy product on digestive symptoms and quality of life in patients with irritable bowel syndrome
| ISRCTN | ISRCTN78863629 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN78863629 |
| Secondary identifying numbers | NU211 |
- Submission date
- 31/05/2007
- Registration date
- 30/08/2007
- Last edited
- 12/09/2013
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Lesley Roberts
Scientific
Scientific
Department of Primary Care and General Practice
Primary Care and Clinical Sciences Building
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
Study information
| Study design | A multicentre, double blind randomised controlled study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Quality of life |
| Scientific title | |
| Study objectives | Irritable Bowel Syndrome (IBS) is a functional bowel disorder in which abdominal pain or discomfort is associated with a change in bowel habit and features of disordered defaecation. IBS is the most common chronic gastrointestinal disorder. The prevalence of IBS in the West Midlands is about 10%, with about half of these patients consulting their General Practitioner (GP) for advice, reassurance or symptom management. IBS is not a life-threatening disease but significantly reduces the quality of life of patients. IBS can have multiple causes and a wide range of symptoms. Symptoms vary greatly between individuals and this makes management of IBS difficult. For the patient, IBS can mean a substantial number of GP visits, prescriptions, tests and days off work, which is important in terms of cost to both the health service and the patient. Hypothesis: To determine the effect of consumption of probiotic yoghurt compared with non-probiotic yoghurt on symptoms of IBS and quality of life in patients with constipation predominant IBS. |
| Ethics approval(s) | Approval received from the Nottingham Local Research Ethics Committee 2 on the 26th January 2007 (ref: 06/Q2404/172). |
| Health condition(s) or problem(s) studied | Irritable Bowel Syndrome (IBS) |
| Intervention | 1. Intervention group: receive two daily servings of a probiotic yoghurt which contains live strains of bacteria 2. Control group: receive two daily servings of a yoghurt that does not contain probiotic bacteria The total duration of the study is 14 weeks, which includes two weeks of completing a daily diary only, followed by 12 weeks of eating two yoghurts daily and completing a daily diary. Participants will meet with a researcher on four occasions. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Probiotic yoghurt |
| Primary outcome measure | The primary outcome measure is the effect on Subjects' Global Assessment (SGA) of IBS symptoms relief at four weeks |
| Secondary outcome measures | 1. Effect on SGA of IBS symptoms relief over 12 weeks and per week 2. Effect on bloating, abdominal pain and flatulence/passage of gas over 4 and 12 weeks and per week 3. Effect on composite score of IBS symptoms (sum of severity score of bloating, abdominal pain and flatulence/passage of gas) over 4 and 12 weeks and per week 4. Effect on bowel function (stool frequency and consistency, bowel movement difficulty) over 4 and 12 weeks and per week 5. Effect on quality of life (IBS-QOL) after 4, 8 and 12 weeks 6. Effect on severity of IBS (IBS-SSS) after 4, 8 and 12 weeks 7. Effect on IBS specific symptoms questionnaire (pain, constipation and diarrhoea) after 4, 8 and 12 weeks 8. Effect on responders rate for SGA of IBS symptoms relief over 1 - 4 weeks and 1 - 12 weeks period (a responder will be defined as a patient who reported satisfactory relief on at least 50% of weeks of the considered period) 9. Effect on responders rate for bloating severity at 4 weeks and 12 weeks (a responder will be defined as a patient who reported at least a 50% decrease of bloating severity at 4 or 12 weeks) |
| Overall study start date | 01/01/2007 |
| Completion date | 30/11/2007 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 240 |
| Key inclusion criteria | 1. Female or male free-living patients aged from 18 to 65 years 2. Patient with a diagnosis of IBS according to Rome III criteria: recurrent abdominal pain or discomfort at least three days per month in the last three months associated with two or more of the following: 2.1. Improvement with defaecation 2.2. Onset associated with a change in frequency of stool 2.3. Onset associated with a change in form (appearance) of stool 3. Patient with a diagnosis of IBS according to Rome III criteria with symptom onset at least six months prior to diagnosis 4. Patient with constipation-predominant symptom profile according to Rome III criteria: hard or lumpy stools (type 1 - 2 of Bristol scale) greater than 25% and loose (mushy) or watery stools (type 6 - 7 of Bristol scale) less than 25% of bowel movement 5. Patient having an Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) score greater than 75 6. Patient passing three or less stools per day during baseline data gathering phase |
| Key exclusion criteria | 1. Patient with a diagnosis of IBS with diarrhoea-predominant, mixed and unsubtyped according to Rome III criteria: loose (mushy) or watery-type 6-7 of Bristol scale) stools greater than 25% and hard or lumpy (type 1-2 of Bristol scale) stools less than 25% of bowel movement 2. Patient with a diagnosis of IBS with clinical signs of alarm (rectorragy, fever, associated inflammatory articular signs, recent weight loss) 3. Commencement of an anti-psychotic medication within the prior month 4. Change of prescribing for IBS-symptoms within the prior month 5. Change of dietary habit within the preceding month 6. Patient with known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease 7. Patient undergoing general anaesthesia in the month prior to inclusion 8. For female patient: 8.1. Pregnant patient or patient planning to become pregnant during the study 8.2. Breast-feeding 9. Patient currently involved in any other clinical trial or having participated in a trial for IBS within the preceding three months 10. Patient with known lactose intolerance or immunodeficiency 11. Patient with known allergy to product component (milk protein for example) 12. Patients who are morbidly obese (Body Mass Index [BMI] greater than 35) or where BMI is less than 18 (as this will be deemed suggestive of abnormal diet or function) 13. Patients with history of laxative abuse |
| Date of first enrolment | 01/01/2007 |
| Date of final enrolment | 30/11/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Department of Primary Care and General Practice
Birmingham
B15 2TT
United Kingdom
B15 2TT
United Kingdom
Sponsor information
Danone Research (France)
Industry
Industry
c/o Nicolas Gausseres
Route Departementale 128
Paris
91767
France
| Website | http://www.danone.com/ |
|---|---|
"ROR" |
https://ror.org/00aj77a24 |
Funders
Funder type
Industry
Groupe Danone (France)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 07/03/2013 | Yes | No |
